CG Oncology (CGON) President & COO to depart as Arthur Kuan named President

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

CG Oncology, Inc. announced that President & Chief Operating Officer Ambaw Bellete will separate from the company effective June 30, 2026, following an agreement reached on May 20, 2026. He is expected to receive severance benefits consistent with Section 4(b) of his 2025 employment agreement.

The company has begun a search for a Chief Commercial Officer and the board has appointed Arthur Kuan as President in addition to his existing roles. His background is described in CG Oncology’s definitive proxy statement filed on April 24, 2026.

Positive

None.

Negative

President & COO departure: Ambaw Bellete’s separation, effective June 30, 2026, represents a significant leadership change in CG Oncology’s senior operating and commercial management team.

Insights

Senior operating executive departs; internal leader expands role as President.

CG Oncology reports that President & Chief Operating Officer Ambaw Bellete will leave effective June 30, 2026, with severance tied to his existing employment agreement. A leadership change at this level can influence commercial execution and internal operations, depending on how responsibilities are redistributed.

The board appointed Arthur Kuan as President on May 20, 2026, adding to his current positions, and launched a search for a Chief Commercial Officer. The filing references Kuan’s existing public biography, suggesting continuity from a known internal leader while the company recruits additional commercial expertise.

Subsequent disclosures may clarify how the new President and future Chief Commercial Officer will divide responsibilities and whether the transition alters CG Oncology’s commercial strategy. For now, the filing primarily signals a governance and management structure shift rather than detailing any immediate strategic or financial changes.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Bellete separation agreement date: May 20, 2026 Bellete separation effective date: June 30, 2026 Employment agreement reference date: January 9, 2025 +3 more

6 metrics

Bellete separation agreement date May 20, 2026 Date company and Ambaw Bellete agreed to separation

Bellete separation effective date June 30, 2026 Effective date of President & COO separation

Employment agreement reference date January 9, 2025 Date of Amended and Restated Employment Agreement governing severance

2024 Form 10-K reference December 31, 2024 year-end Fiscal year end cited for 10-K containing Exhibit 10.12

Proxy statement filing date April 24, 2026 Date definitive Schedule 14A with Kuan biography was filed

8-K signature date May 26, 2026 Date CG Oncology executed the current report

Key Terms

Emerging growth company, general release and waiver of claims, Amended and Restated Employment Agreement, definitive proxy statement, +2 more

6 terms

Emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors or Certain Officers;"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

general release and waiver of claims legal

"provides for a general release and waiver of claims against the Company,"

Amended and Restated Employment Agreement legal

"Section 4(b) of his Amended and Restated Employment Agreement, effective January 9, 2025"

definitive proxy statement regulatory

"the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities"

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

Schedule 14A regulatory

"the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities"

Schedule 14A is a document that companies file with regulators to share important information with shareholders before a big vote, like approving a merger or election of directors. It matters because it helps investors understand what’s happening so they can make informed decisions about the company’s future.

severance benefits financial

"pursuant to which Mr. Bellete will receive the severance benefits set forth in Section 4(b)"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

05/26/2026 - 08:00 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

      Date of Report (Date of earliest event reported): May 20, 2026

     

CG Oncology, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-41925	37-1611499
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3000 Pegasus Park Drive Suite 1640
Dallas, Texas		75247
(Address of Principal Executive Offices)		(Zip Code)

      Registrant’s Telephone Number, Including Area Code: (949) 409-3700

     

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	CGON	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Bellete Separation

On May 20, 2026, CG Oncology, Inc. (the “Company”) and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026. The Company thanks Mr. Bellete for his contributions and wishes him well in his next endeavors.

The Company expects to enter into a separation agreement with Mr. Bellete that provides for a general release and waiver of claims against the Company, and pursuant to which Mr. Bellete will receive the severance benefits set forth in Section 4(b) of his Amended and Restated Employment Agreement, effective January 9, 2025 and filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 28, 2025.

The Company has initiated a search for a Chief Commercial Officer.

Kuan Appointment as President

On May 20, 2026, the Company’s Board of Directors also approved the appointment of Arthur Kuan as President of the Company, in addition to his other positions, in connection with Mr. Bellete’s separation. Mr. Kuan’s biographical information is set forth under the section titled “Election of Directors” in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities (File No. 333-290108), filed with the SEC on April 24, 2026, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	CG Oncology, Inc.

Date: May 26, 2026	By: /s/ Josh Patterson
	Name: Josh Patterson
	Title: General Counsel, Chief Compliance Officer and Secretary

Source: View Original Filing on SEC EDGAR

FAQ

What leadership change did CG Oncology (CGON) announce in this 8-K?

CG Oncology reported that President & Chief Operating Officer Ambaw Bellete will separate from the company effective June 30, 2026. The decision was agreed on May 20, 2026, and the company expressed appreciation for his contributions and future endeavors.

Will Ambaw Bellete receive severance from CG Oncology (CGON)?

Yes. CG Oncology expects to enter a separation agreement under which Ambaw Bellete will receive severance benefits provided in Section 4(b) of his Amended and Restated Employment Agreement dated January 9, 2025, referenced in the company’s 2024 Form 10-K filing.

Who has been appointed President of CG Oncology (CGON)?

The board appointed Arthur Kuan as President on May 20, 2026, in addition to his other positions. His biographical information appears in the company’s definitive proxy statement on Schedule 14A filed with the SEC on April 24, 2026.

What new executive search is CG Oncology (CGON) conducting?

CG Oncology has initiated a search for a Chief Commercial Officer following Ambaw Bellete’s planned separation. This role is expected to support the company’s commercial and operational activities alongside the newly appointed President, Arthur Kuan.

When does CG Oncology (CGON) expect Ambaw Bellete’s separation to become effective?

The separation of President & Chief Operating Officer Ambaw Bellete is expected to become effective on June 30, 2026. The agreement on his departure was reached on May 20, 2026, with severance to follow his existing employment contract terms.

Where can investors find more information about CG Oncology (CGON) President Arthur Kuan?

Arthur Kuan’s biographical information is incorporated by reference from CG Oncology’s definitive proxy statement on Schedule 14A. That document was filed with the SEC on April 24, 2026 and describes his background and roles with the company.

Filing Exhibits & Attachments

1 document